SPY327.94-10.28 -3.04%
DIA266.26-8.40 -3.06%
IXIC11,062.28-369.07 -3.23%

Royalty Pharma Priced Secondary Offering of 17.3M Class A Ordinary Shares by Selling Shareholders @$42/Share

Royalty Pharma plc (the "Company") (NASDAQ: RPRX) announced the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1 filed with the U.S.

· 10/16/2020 05:45
Royalty Pharma plc (the "Company") (NASDAQ:RPRX) announced the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission ("SEC") at a price to the public of $42.00 per share. The selling shareholders have granted the underwriters an option to purchase up to 2,601,455 additional Class A ordinary shares. The Company will not receive any of the proceeds from the sale of its Class A ordinary shares by the selling shareholders. The offering is expected to close on October 20, 2020, subject to customary closing conditions. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC and Citigroup are acting as joint lead book-running managers and as representatives of the underwriters for the proposed offering. Cowen, Evercore ISI, Truist Securities and UBS Investment Bank are also acting as joint book-running managers for the offering. BBVA, DNB Markets, Scotiabank, TD Securities, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.